UroGen Pharma (URGN) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UPDATE: UroGen Pharma (URGN) Reports Exclusive License Agreement with Agenus (AGEN) to Advance Treatment of Urinary Tract Cancers
November 11, 2019 8:03 AM EST(Updated - November 11, 2019 8:03 AM EST)
UroGen Pharma Ltd. (NASDAQ: URGN) today announced that it has entered into an exclusive worldwide1 license agreement with Agenus Inc (NASDAQ: AGEN) to develop and commercialize zalifrelimab (AGEN1884, anti-CTLA-4 antibody) via intravesical delivery in combination with UGN-201 for the treatment of urinary tract cancers. This combination is based on encouraging preclinical data utilizing UroGens proprietary sustained release technology, which is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option while... More
